CRISPR-related methods and compositions targeting PTPN2 expression
CRISPR/Cas systems, specifically using modified Cas12a proteins and guide RNAs, address the challenge of targeting PTPN2 gene expression in T cells, improving their therapeutic potential through precise editing.
JP2026519521APending Publication Date: 2026-06-16EDITAS MEDICINE INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- EDITAS MEDICINE INC
- Filing Date
- 2024-05-24
- Publication Date
- 2026-06-16
AI Technical Summary
Technical Problem
Current methods are inadequate for effectively targeting and regulating PTPN2 gene expression, particularly in the context of immunotherapeutic approaches using CRISPR/Cas systems, which is crucial for modulating T cell function.
Method used
The use of CRISPR/Cas-related systems, including modified Cas12a proteins and guide RNAs, to induce targeted editing of PTPN2 nucleic acid sequences, leading to indels or gene knockouts in cells such as T cells, enhancing their therapeutic potential.
Benefits of technology
This approach enables precise manipulation of T cell function, improving their potency in immunotherapeutic applications by altering PTPN2 expression, thereby enhancing therapeutic efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026519521000001_ABST
Abstract
This disclosure relates to CRISPR-related systems and components for targeting, editing, and / or regulating the expression of the PTPN2 (protein tyrosine phosphatase nonreceptor type 2) gene. This disclosure also relates to methods and applications relating to genetically modified cells, including T cells or T cell progenitor cells.
Need to check novelty before this filing date? Find Prior Art